Israel's widespread airstrikes on Iran effectively damaged the country's nuclear and ballistic missile programs, which ...

Risk is no longer confined to a compliance checklist. These four challenges highlight how the landscape is changing and what ...

Threats will only continue to become more complex as new technologies advance. According to a 2024 Microsoft report, its threat intelligence department now tracks “more than 1,500 unique threat groups ...

Shares of Sarepta Therapeutics closed down as much as 42% to hit a nine-year low of $18.30 on Monday after a second death of ...

It is clear that Iran has suffered significant damage to its leadership, its military and industrial capabilities, and ...

Francois-Henri Pinault's decision to hire Renault boss Luca de Meo is an audacious but necessary move to address the twin ...

New research links semaglutide and tirzepatide, which are GLP-1 agonists used to treat type 2 diabetes and aid weight loss, ...

Minnesota lawmaker shooting suspect Vance Luther Boelter is in custody, but bad-faith responses by figures like Elon Musk and ...

CCCC's valuation is unjustifiably low, trading at half its liquidity despite a promising pipeline and no imminent cash crisis ...

Last Thursday, a federal judge in San Francisco issued a temporary restraining order against President Donald Trump's ...

The instinctive reaction to the ESG and DEI “vibe shift” in the US was to persist, defend the status quo, and write off what was happening over there as an isolated phenomenon.

A second patient has died following treatment with Sarepta Therapeutics’ Elevidys, raising more doubts about the Duchenne muscular dystrophy (DMD) gene therapy’s safety profile. | A second patient has ...